1	Nitric	Nitric	B-NP	JJ	B-protein	3	NMOD	-1
2	oxide	oxide	I-NP	NN	I-protein	3	NMOD	-1
3	synthase	synthase	I-NP	NN	I-protein	4	NMOD	-1
4	inhibition	inhibition	I-NP	NN	O	5	SUB	18	inhibition
5	results	result	B-VP	VBZ	O	0	ROOT	17	results
6	in	in	B-PP	IN	O	5	VMOD	-1
7	synergistic	synergistic	B-NP	JJ	O	9	NMOD	-1
8	anti-tumour	anti-tumour	I-NP	JJ	O	9	NMOD	-1
9	activity	activity	I-NP	NN	O	6	PMOD	18	activity
10	with	with	B-PP	IN	O	9	NMOD	-1
11	melphalan	melphalan	B-NP	NN	O	19	NMOD	-1
12	and	and	O	CC	O	19	NMOD	-1
13	tumour	tumour	B-NP	NN	B-protein	19	NMOD	-1
14	necrosis	necrosis	I-NP	NN	I-protein	19	NMOD	0
15	factor	factor	I-NP	NN	I-protein	19	NMOD	-1
16	alpha-based	alpha-based	I-NP	JJ	O	19	NMOD	-1
17	isolated	isolate	I-NP	VBN	O	19	NMOD	0
18	limb	limb	I-NP	NN	O	19	NMOD	-1
19	perfusions	perfusion	I-NP	NNS	O	10	PMOD	-1
20	.	.	O	.	O	5	P	-1

1	Nitric	Nitric	B-NP	JJ	O	2	NMOD	-1
2	oxide	oxide	I-NP	NN	O	6	SUB	-1
3	(	(	O	(	O	5	DEP	-1
4	NO	NO	B-NP	NN	O	5	DEP	-1
5	)	)	O	)	O	2	NMOD	-1
6	is	be	B-VP	VBZ	O	0	ROOT	-1
7	an	an	B-NP	DT	O	9	NMOD	-1
8	important	important	I-NP	JJ	O	9	NMOD	0
9	molecule	molecule	I-NP	NN	O	6	PRD	-1
10	in	in	B-PP	IN	O	9	NMOD	-1
11	regulating	regulate	B-VP	VBG	O	10	PMOD	0
12	tumour	tumour	B-NP	NN	O	14	NMOD	-1
13	blood	blood	I-NP	NN	O	14	NMOD	-1
14	flow	flow	I-NP	NN	O	11	OBJ	-1
15	and	and	O	CC	O	6	VMOD	-1
16	stimulating	stimulate	B-VP	VBG	O	6	VMOD	17	stimulating
17	tumour	tumour	B-NP	NN	O	18	NMOD	-1
18	angiogenesis	angiogenesis	I-NP	NN	O	16	OBJ	3	angiogenesis
19	.	.	O	.	O	6	P	-1

1	Inhibition	Inhibition	B-NP	NN	O	7	SUB	18	Inhibition
2	of	of	B-PP	IN	O	1	NMOD	-1
3	NO	NO	B-NP	NN	B-protein	4	NMOD	-1
4	synthase	synthase	I-NP	NN	I-protein	2	PMOD	-1
5	by	by	B-PP	IN	O	1	NMOD	-1
6	L-NAME	L-NAME	B-NP	NN	B-protein	5	PMOD	-1
7	might	might	B-VP	MD	O	0	ROOT	-1
8	induce	induce	I-VP	VB	O	7	VC	17	induce
9	an	an	B-NP	DT	O	11	NMOD	-1
10	anti-tumour	anti-tumour	I-NP	JJ	O	11	NMOD	-1
11	effect	effect	I-NP	NN	O	8	OBJ	18	effect
12	by	by	B-PP	IN	O	8	VMOD	-1
13	limiting	limit	B-VP	VBG	O	14	NMOD	18	limiting
14	nutrients	nutrient	B-NP	NNS	O	12	PMOD	-1
15	and	and	O	CC	O	8	VMOD	-1
16	oxygen	oxygen	B-NP	NN	O	8	VMOD	-1
17	to	to	B-VP	TO	O	18	VMOD	-1
18	reach	reach	I-VP	VB	O	16	NMOD	14	reach
19	tumour	tumour	B-NP	NN	O	20	NMOD	-1
20	tissue	tissue	I-NP	NN	O	18	OBJ	-1
21	or	or	O	CC	O	18	VMOD	-1
22	affecting	affect	B-VP	VBG	O	18	VMOD	16	affecting
23	vascular	vascular	B-NP	JJ	O	24	NMOD	-1
24	growth	growth	I-NP	NN	O	22	OBJ	4	growth
25	.	.	O	.	O	7	P	-1

1	The	The	B-NP	DT	O	3	NMOD	-1
2	anti-tumour	anti-tumour	I-NP	JJ	O	3	NMOD	-1
3	effect	effect	I-NP	NN	O	9	SUB	18	effect
4	of	of	B-PP	IN	O	3	NMOD	-1
5	L-NAME	L-NAME	B-NP	NN	B-protein	4	PMOD	-1
6	after	after	B-SBAR	IN	O	3	NMOD	-1
7	systemic	systemic	B-NP	JJ	O	8	NMOD	-1
8	administration	administration	I-NP	NN	O	6	PMOD	19	administration
9	was	be	B-VP	VBD	O	0	ROOT	-1
10	studied	study	I-VP	VBN	O	9	VC	-1
11	in	in	B-PP	IN	O	10	VMOD	-1
12	a	a	B-NP	DT	O	17	NMOD	-1
13	renal	renal	I-NP	JJ	O	17	NMOD	-1
14	subcapsular	subcapsular	I-NP	JJ	O	17	NMOD	-1
15	CC531	CC531	I-NP	NN	O	17	NMOD	-1
16	adenocarcinoma	adenocarcinoma	I-NP	NN	O	17	NMOD	-1
17	model	model	I-NP	NN	O	11	PMOD	-1
18	in	in	B-PP	IN	O	17	NMOD	-1
19	rats	rat	B-NP	NNS	O	18	PMOD	-1
20	.	.	O	.	O	9	P	-1

1	Moreover	Moreover	B-ADVP	RB	O	15	VMOD	-1
2	,	,	O	,	O	15	P	-1
3	regional	regional	B-NP	JJ	O	4	NMOD	-1
4	administration	administration	I-NP	NN	O	15	SUB	19	administration
5	of	of	B-PP	IN	O	4	NMOD	-1
6	L-NAME	L-NAME	B-NP	NN	B-protein	5	PMOD	-1
7	,	,	O	,	O	4	P	-1
8	in	in	B-PP	IN	O	4	NMOD	-1
9	combination	combination	B-NP	NN	O	8	PMOD	-1
10	with	with	B-PP	IN	O	9	NMOD	-1
11	TNF	TNF	B-NP	NN	B-protein	13	NMOD	-1
12	and	and	I-NP	CC	O	13	NMOD	-1
13	melphalan	melphalan	I-NP	NN	O	10	PMOD	-1
14	,	,	O	,	O	4	P	-1
15	was	be	B-VP	VBD	O	0	ROOT	-1
16	studied	study	I-VP	VBN	O	15	VC	-1
17	in	in	B-PP	IN	O	16	VMOD	-1
18	an	an	B-NP	DT	O	21	NMOD	-1
19	isolated	isolate	I-NP	VBN	O	21	NMOD	0
20	limb	limb	I-NP	NN	O	21	NMOD	-1
21	perfusion	perfusion	I-NP	NN	O	25	NMOD	0
22	(	(	O	(	O	24	DEP	-1
23	ILP	ILP	B-NP	NN	O	24	DEP	-1
24	)	)	O	)	O	21	NMOD	-1
25	model	model	B-NP	NN	O	17	PMOD	-1
26	using	use	B-VP	VBG	O	15	VMOD	-1
27	BN175	BN175	B-NP	NN	O	29	NMOD	-1
28	soft-tissue	soft-tissue	I-NP	JJ	O	29	NMOD	-1
29	sarcomas	sarcoma	I-NP	NNS	O	26	OBJ	-1
30	.	.	O	.	O	15	P	-1

1	Systemic	Systemic	B-NP	JJ	O	2	NMOD	-1
2	treatment	treatment	I-NP	NN	O	5	SUB	19	treatment
3	with	with	B-PP	IN	O	2	NMOD	-1
4	L-NAME	L-NAME	B-NP	NN	B-protein	3	PMOD	-1
5	inhibited	inhibit	B-VP	VBD	O	0	ROOT	18	inhibited
6	growth	growth	B-NP	NN	O	5	OBJ	4	growth
7	of	of	B-PP	IN	O	6	NMOD	-1
8	adenocarcinoma	adenocarcinoma	B-NP	NN	O	7	PMOD	-1
9	significantly	significantly	B-ADVP	RB	O	5	VMOD	-1
10	but	but	O	CC	O	5	VMOD	-1
11	was	be	B-VP	VBD	O	5	VMOD	-1
12	accompanied	accompany	I-VP	VBN	O	11	VC	-1
13	by	by	B-PP	IN	O	12	VMOD	-1
14	impaired	impaired	B-NP	JJ	O	16	NMOD	18	impaired
15	renal	renal	I-NP	JJ	O	16	NMOD	-1
16	function	function	I-NP	NN	O	13	PMOD	-1
17	.	.	O	.	O	5	P	-1

1	In	In	B-PP	IN	O	4	VMOD	-1
2	ILP	ILP	B-NP	NN	O	1	PMOD	-1
3	,	,	O	,	O	4	P	-1
4	reduced	reduce	B-VP	VBD	O	0	ROOT	18	reduced
5	tumour	tumour	B-NP	NN	O	6	NMOD	-1
6	growth	growth	I-NP	NN	O	7	SUB	4	growth
7	was	be	B-VP	VBD	O	4	VMOD	-1
8	observed	observe	I-VP	VBN	O	7	VC	0
9	when	when	B-ADVP	WRB	O	7	VMOD	-1
10	L-NAME	L-NAME	B-NP	NN	B-protein	11	SUB	-1
11	was	be	B-VP	VBD	O	9	SBAR	-1
12	used	use	I-VP	VBN	O	11	VC	0
13	alone	alone	B-ADVP	RB	O	12	VMOD	-1
14	.	.	O	.	O	4	P	-1

1	In	In	B-PP	IN	O	9	VMOD	-1
2	combination	combination	B-NP	NN	O	1	PMOD	-1
3	with	with	B-PP	IN	O	2	NMOD	-1
4	TNF	TNF	B-NP	NN	B-protein	6	NMOD	-1
5	or	or	I-NP	CC	O	6	NMOD	-1
6	melphalan	melphalan	I-NP	NN	O	3	PMOD	-1
7	,	,	O	,	O	9	P	-1
8	L-NAME	L-NAME	B-NP	NN	B-protein	9	SUB	-1
9	increased	increase	B-VP	VBD	O	0	ROOT	0
10	response	response	B-NP	NN	O	11	NMOD	0
11	rates	rate	I-NP	NNS	O	9	OBJ	-1
12	significantly	significantly	B-VP	RB	O	13	VMOD	-1
13	compared	compare	I-VP	VBN	O	11	NMOD	-1
14	to	to	B-PP	TO	O	13	VMOD	-1
15	perfusions	perfusion	B-NP	NNS	O	14	PMOD	-1
16	without	without	B-PP	IN	O	15	NMOD	-1
17	L-NAME	L-NAME	B-NP	NN	B-protein	16	PMOD	-1
18	(	(	O	(	O	25	DEP	-1
19	0-64	0-64	B-NP	CD	O	20	NMOD	-1
20	%	%	I-NP	NN	O	23	NMOD	-1
21	and	and	O	CC	O	23	NMOD	-1
22	0-63	0-63	B-NP	CD	O	23	NMOD	-1
23	%	%	I-NP	NN	O	25	DEP	-1
24	respectively	respectively	B-ADVP	RB	O	23	VMOD	-1
25	)	)	O	)	O	17	NMOD	-1
26	.	.	O	.	O	9	P	-1

1	An	An	B-NP	DT	O	4	NMOD	-1
2	additional	additional	I-NP	JJ	O	4	NMOD	-1
3	anti-tumour	anti-tumour	I-NP	JJ	O	4	NMOD	-1
4	effect	effect	I-NP	NN	O	5	SUB	18	effect
5	was	be	B-VP	VBD	O	0	ROOT	-1
6	demonstrated	demonstrate	I-VP	VBN	O	5	VC	-1
7	when	when	B-ADVP	WRB	O	6	VMOD	-1
8	L-NAME	L-NAME	B-NP	NN	B-protein	9	SUB	-1
9	was	be	B-VP	VBD	O	7	SBAR	-1
10	added	add	I-VP	VBN	O	9	VC	19	added
11	to	to	B-PP	TO	O	10	VMOD	-1
12	the	the	B-NP	DT	O	14	NMOD	-1
13	synergistic	synergistic	I-NP	JJ	O	14	NMOD	-1
14	combination	combination	I-NP	NN	O	11	PMOD	-1
15	of	of	B-PP	IN	O	14	NMOD	-1
16	melphalan	melphalan	B-NP	NN	O	20	NMOD	-1
17	and	and	I-NP	CC	O	20	NMOD	-1
18	TNF	TNF	I-NP	NN	B-protein	20	NMOD	-1
19	(	(	O	(	O	20	NMOD	-1
20	responses	response	B-NP	NNS	O	15	PMOD	-1
21	increased	increase	B-VP	VBD	O	6	VMOD	0
22	from	from	B-PP	IN	O	21	VMOD	-1
23	70	70	B-NP	CD	O	22	PMOD	-1
24	to	to	I-NP	TO	O	22	PMOD	-1
25	100	100	I-NP	CD	O	24	PMOD	-1
26	%	%	I-NP	NN	O	22	PMOD	-1
27	)	)	O	)	O	6	VMOD	-1
28	.	.	O	.	O	5	P	-1

1	Inhibition	Inhibition	B-NP	NN	O	5	SUB	18	Inhibition
2	of	of	B-PP	IN	O	1	NMOD	-1
3	NO	NO	B-NP	NN	B-protein	4	NMOD	-1
4	synthase	synthase	I-NP	NN	I-protein	2	PMOD	-1
5	reduces	reduce	B-VP	VBZ	O	0	ROOT	18	reduces
6	tumour	tumour	B-NP	NN	O	7	NMOD	-1
7	growth	growth	I-NP	NN	O	5	OBJ	4	growth
8	both	both	B-PP	CC	O	9	PMOD	-1
9	after	after	B-PP	IN	O	5	VMOD	-1
10	systemic	systemic	B-NP	JJ	O	12	NMOD	-1
11	and	and	I-NP	CC	O	12	NMOD	-1
12	regional	regional	I-NP	JJ	O	9	PMOD	-1
13	(	(	O	(	O	15	DEP	-1
14	ILP	ILP	B-NP	NN	O	15	DEP	-1
15	)	)	O	)	O	12	NMOD	-1
16	treatment	treatment	B-NP	NN	O	12	NMOD	0
17	.	.	O	.	O	5	P	-1

1	A	A	B-NP	DT	O	4	NMOD	-1
2	synergistic	synergistic	I-NP	JJ	O	4	NMOD	-1
3	anti-tumour	anti-tumour	I-NP	JJ	O	4	NMOD	-1
4	effect	effect	I-NP	NN	O	7	SUB	18	effect
5	of	of	B-PP	IN	O	4	NMOD	-1
6	L-NAME	L-NAME	B-NP	NN	B-protein	5	PMOD	-1
7	is	be	B-VP	VBZ	O	0	ROOT	-1
8	observed	observe	I-VP	VBN	O	7	VC	0
9	in	in	B-PP	IN	O	8	VMOD	-1
10	combination	combination	B-NP	NN	O	9	PMOD	-1
11	with	with	B-PP	IN	O	10	NMOD	-1
12	melphalan	melphalan	B-NP	NN	O	14	NMOD	-1
13	and/or	and/or	O	CC	O	14	NMOD	-1
14	TNF	TNF	B-NP	NN	B-protein	11	PMOD	-1
15	using	use	B-VP	VBG	O	14	NMOD	-1
16	ILP	ILP	B-NP	NN	B-protein	15	OBJ	-1
17	.	.	O	.	O	7	P	-1

1	These	These	B-NP	DT	O	2	NMOD	-1
2	results	result	I-NP	NNS	O	3	SUB	0
3	indicate	indicate	B-VP	VBP	O	0	ROOT	-1
4	a	a	B-NP	DT	O	6	NMOD	-1
5	possible	possible	I-NP	JJ	O	6	NMOD	-1
6	role	role	I-NP	NN	O	3	OBJ	16	role
7	of	of	B-PP	IN	O	6	NMOD	-1
8	L-NAME	L-NAME	B-NP	NN	B-protein	7	PMOD	-1
9	for	for	B-PP	IN	O	6	NMOD	-1
10	the	the	B-NP	DT	O	11	NMOD	-1
11	treatment	treatment	I-NP	NN	O	9	PMOD	19	treatment
12	of	of	B-PP	IN	O	11	NMOD	-1
13	solid	solid	B-NP	JJ	O	14	NMOD	-1
14	tumours	tumour	I-NP	NNS	O	12	PMOD	-1
15	in	in	B-PP	IN	O	11	NMOD	-1
16	a	a	B-NP	DT	O	20	NMOD	-1
17	systemic	systemic	I-NP	JJ	O	20	NMOD	-1
18	or	or	I-NP	CC	O	20	NMOD	-1
19	regional	regional	I-NP	JJ	O	20	NMOD	-1
20	setting	setting	I-NP	NN	O	15	PMOD	-1
21	.	.	O	.	O	3	P	-1

